Bruno Victor graduated in Biochemistry from the Faculty of Sciences and Technology of the University of Coimbra in 2001. After two years as a research student, under the supervision of Claudio Soares, he started his PhD at ITQB-UNL. At that time, his project consisted of using different molecular modeling methods to study electron transfer proteins involved in the O2 and NO metabolism. After completing his PhD in biochemistry, he continued at ITQB-UNL where he started a Post-Doc project, focused on the study of the functional activity of hemagglutinin and several of its functional peptides in the infection of Influenza Viruses. During this period, with an HPC Europe 2 fellowship, he was also a visiting researcher at Xavier Daura Lab in Barcelona, where he had the opportunity to work with outstanding computational resources, such as the Barcelona Supercomputer. In 2012, he joined BSIM Therapeutics as a computational research scientist, to develop new methods and approaches (from chemoinformatics to Quantum Mechanics) to improve the identification and development of new therapeutic agents to treat Transthyretin-related amyloid diseases. During this period, he was involved not only in this company’s work but also in multiple drug discovery projects (from target and lead identification and validation, to in vitro evaluation) as an outsourced computational scientist, collaborating with different small biotech and drug discovery companies (GenePrediT and BiosolveIT). Although the results of some of those projects did not evolve into real applications, some others are still under development. One such promising example is the work I contributed to the development of a set of new therapeutic agents to prevent the formation of ATTR fibril formation in the peripheral and central nervous system. After this period in industry, he continued to develop his research focused on multiple drug discovery projects, in different academic groups, ranging from the University of Coimbra to the University of Lisbon. Between 2019 and 2023 he was an auxiliary researcher at the BioISI research center, where he coordinated the Structure-based drug discovery research group. During this time he supervised 1 Post-Doc, 3 PhD students, 13 Master thesis, and 5 undergraduate students. Under his supervision, the team has been involved in multiple drug discovery projects. During this time he coordinated several competitively funded projects by FCT (PTDC/BIA-BFS/28419/2017 - development of innovative methods to identify membrane Pan-Assay Interference Compounds (PAINS), and BioISI (BioISI projects call – 2020 - study of post-translational modifications in different metabolic enzymes). He also was part of other FCT-funded projects as part of the team, always responsible for the coordination of the computational work (PTDC/QEQ-MED/29036/2017 and PTDC/QUI-QFI/28455/2017). Moreover, he was involved in two collaborative projects with two international companies developing software tools for drug discovery (Lhasa and BiosolveIT), which are part of the PhD and Master projects of two of his students. In 2023 he joined Zymvol Biomodeling, a biotech company dedicated to protein discovery and engineering, with biotechnological applications. In May 2024 he decided to move to CoLAB AccelBio, to lead the computational medicinal chemistry research department to help setup and develop ongoing drug discovery projects Overall, he published 33 papers in specialized journals and he has registered 3 patents. His research is focused on Natural Sciences with an emphasis on Computational Biochemistry, Biophysics, and Medicinal Chemistry. During his professional activities, he has interacted and collaborated with 105 collaborator(s) during his scientific work.